COVID-19 Vaccine Hesitancy in Middle-Aged and Older Adults in India: A Mixed-Methods Study – Cureus

by | Oct 16, 2022 | COVID-19

In December 2019, the world saw the first case of COVID-19 in Wuhan, a city of Hubei province, China, and the WHO declared a pandemic on March 11, 2020 [1]. The symptoms of this novel and rapidly spreading disease were largely unknown but were shown to impact physical, mental, and cognitive health [2]. The pandemic had caused enormous disruption to human life and the world economy, presenting an extraordinary challenge to global health [3]. With the rise in the number of cases and COVID-19-related deaths, vaccine development was accelerated, and several pharmaceutical companies began large-scale clinical trials to test new vaccines, including those that were in the early stages of development [3]. There was a rapid development of vaccines to tackle the SARS-CoV-2 virus, particularly by BioTech, Moderna and Johnson & Johnson [3]. In India, three vaccines, Covishield, developed by the Serum Institute of India, Covaxin, developed by Bharat Biotech, and Sputnik V, developed by the Gameleya Research Institute of Epidemiology and Microbiology, also gained approval from the Central Drugs Standard Control Organisation (CDSCO) [4].
The COVID-19 outbreak in India began in Thrissur, Kerala after a few students returned from Wuhan, China [5]. The first wave of the COVID-19 pandemic in India began in March 2020 with thousands of daily infections, but by February 2021, the curve of COVID-19 cases had flattened. However, the spiralling cases during the second wave of the …

Article Attribution | Read More at Article Source

Share This